FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076055319> ?p ?o ?g. }

• W2076055319 endingPage "73" @default.
• W2076055319 startingPage "65" @default.
• W2076055319 abstract "Resistance (R) among Gram-positive cocci has escalated in the last two decades to levels necessitating the development and use in the newer drug classes, oxazolidinones (linezolid) and streptogramins (quinupristin/dalfopristin [Q/D]). The SENTRY Antimicrobial Surveillance Program has monitored these classes before, during and after their release by various regulatory agencies. Over 30,000 Gram-positive strains were tested against >30 drugs by reference broth microdilution methods between 1998-2000 in four geographic regions (Asia-Western Pacific [APAC], Europe [EU], Latin America [LA], North America [NA]). The tested strains were 23,188 staphylococci; 5,103 enterococci and 2,045 streptococci. Among staphylococci, linezolid was active against all isolates (MICs, < or =4 microg/ml) regardless of susceptibility patterns of other antimicrobial agents. Similar results were noted for vancomycin (includes one VISA from Hong Kong), teicoplanin, and Q/D (<1% R). Gatifloxacin had the widest spectrum among fluoroquinolones (FQ) against Staphylococcus aureus (1.5-9.2% R) and coagulase-negative staphylococci (0.8-4.0%). Linezolid was also active against all enterococci (MIC50 and (90,) 2 microg/ml). Q/D was active against only 75.3% of vancomycin-resistant enterococci (VRE). The VRE rate was highest in NA (12.4%) > EU (3.2%) > LA (1.6%) > APAC (1.3%). Among streptococci, linezolid was consistently active (MIC(90,) 1 microg/ml) as were the glycopeptides and Q/D. Variable penicillin-R (MIC, > or = 2 microg/ml) was observed among regions: EU (32.5%) > APAC (15.1%) > LA (13.8%) > NA (9.6%), and macrolide-R was higher in EU (40.3%). Ciprofloxacin-R at > or =4 microg/ml in streptococcal strains was noted world wide highest in viridans group streptococci (18.4-25.6%). Linezolid remained active (MIC, < or =4 microg/ml) against all Gram-positive species strains tested in the SENTRY Program (1998-2000). Q/D, glycopeptides and newer FQ compounds were generally less effective in vitro. It remains a prudent practice to continue surveillance programs to detect emerging resistance patterns and recognize significant regional variations in the oxazolidinone susceptibilities." @default.
• W2076055319 created "2016-06-24" @default.
• W2076055319 creator A5001906344 @default.
• W2076055319 creator A5022028449 @default.
• W2076055319 creator A5044679653 @default.
• W2076055319 creator A5053492923 @default.
• W2076055319 date "2002-05-01" @default.
• W2076055319 modified "2023-09-29" @default.
• W2076055319 title "Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998–2000" @default.
• W2076055319 cites W1518464227 @default.
• W2076055319 cites W1731079655 @default.
• W2076055319 cites W1965078590 @default.
• W2076055319 cites W1974806459 @default.
• W2076055319 cites W2003016647 @default.
• W2076055319 cites W2047649930 @default.
• W2076055319 cites W2053522748 @default.
• W2076055319 cites W2077491736 @default.
• W2076055319 cites W2082395198 @default.
• W2076055319 cites W2084883112 @default.
• W2076055319 cites W2090505190 @default.
• W2076055319 cites W2092196558 @default.
• W2076055319 cites W2107613955 @default.
• W2076055319 cites W2113353811 @default.
• W2076055319 cites W2116876011 @default.
• W2076055319 cites W2126524876 @default.
• W2076055319 cites W2132319419 @default.
• W2076055319 cites W2133816029 @default.
• W2076055319 cites W2134137013 @default.
• W2076055319 cites W2140140625 @default.
• W2076055319 cites W2141695283 @default.
• W2076055319 cites W2145525195 @default.
• W2076055319 cites W2148488439 @default.
• W2076055319 cites W2150324756 @default.
• W2076055319 cites W2151859311 @default.
• W2076055319 cites W2159490829 @default.
• W2076055319 cites W2166227847 @default.
• W2076055319 cites W2168207172 @default.
• W2076055319 cites W2168635615 @default.
• W2076055319 cites W2336287850 @default.
• W2076055319 cites W2916656065 @default.
• W2076055319 doi "https://doi.org/10.1016/s0732-8893(02)00371-1" @default.
• W2076055319 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12052631" @default.
• W2076055319 hasPublicationYear "2002" @default.
• W2076055319 type Work @default.
• W2076055319 sameAs 2076055319 @default.
• W2076055319 citedByCount "67" @default.
• W2076055319 countsByYear W20760553192012 @default.
• W2076055319 countsByYear W20760553192013 @default.
• W2076055319 countsByYear W20760553192014 @default.
• W2076055319 countsByYear W20760553192016 @default.
• W2076055319 countsByYear W20760553192017 @default.
• W2076055319 countsByYear W20760553192019 @default.
• W2076055319 countsByYear W20760553192021 @default.
• W2076055319 countsByYear W20760553192023 @default.
• W2076055319 crossrefType "journal-article" @default.
• W2076055319 hasAuthorship W2076055319A5001906344 @default.
• W2076055319 hasAuthorship W2076055319A5022028449 @default.
• W2076055319 hasAuthorship W2076055319A5044679653 @default.
• W2076055319 hasAuthorship W2076055319A5053492923 @default.
• W2076055319 hasConcept C174802600 @default.
• W2076055319 hasConcept C176947019 @default.
• W2076055319 hasConcept C2776703206 @default.
• W2076055319 hasConcept C2777653605 @default.
• W2076055319 hasConcept C2777874012 @default.
• W2076055319 hasConcept C2778512257 @default.
• W2076055319 hasConcept C2778980435 @default.
• W2076055319 hasConcept C2779489039 @default.
• W2076055319 hasConcept C2780944852 @default.
• W2076055319 hasConcept C2780950330 @default.
• W2076055319 hasConcept C2781414143 @default.
• W2076055319 hasConcept C3019249092 @default.
• W2076055319 hasConcept C4937899 @default.
• W2076055319 hasConcept C501593827 @default.
• W2076055319 hasConcept C523546767 @default.
• W2076055319 hasConcept C54355233 @default.
• W2076055319 hasConcept C71924100 @default.
• W2076055319 hasConcept C86803240 @default.
• W2076055319 hasConcept C89423630 @default.
• W2076055319 hasConceptScore W2076055319C174802600 @default.
• W2076055319 hasConceptScore W2076055319C176947019 @default.
• W2076055319 hasConceptScore W2076055319C2776703206 @default.
• W2076055319 hasConceptScore W2076055319C2777653605 @default.
• W2076055319 hasConceptScore W2076055319C2777874012 @default.
• W2076055319 hasConceptScore W2076055319C2778512257 @default.
• W2076055319 hasConceptScore W2076055319C2778980435 @default.
• W2076055319 hasConceptScore W2076055319C2779489039 @default.
• W2076055319 hasConceptScore W2076055319C2780944852 @default.
• W2076055319 hasConceptScore W2076055319C2780950330 @default.
• W2076055319 hasConceptScore W2076055319C2781414143 @default.
• W2076055319 hasConceptScore W2076055319C3019249092 @default.
• W2076055319 hasConceptScore W2076055319C4937899 @default.
• W2076055319 hasConceptScore W2076055319C501593827 @default.
• W2076055319 hasConceptScore W2076055319C523546767 @default.
• W2076055319 hasConceptScore W2076055319C54355233 @default.
• W2076055319 hasConceptScore W2076055319C71924100 @default.
• W2076055319 hasConceptScore W2076055319C86803240 @default.
• W2076055319 hasConceptScore W2076055319C89423630 @default.
• W2076055319 hasIssue "1" @default.

• next